18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. J Thorac Oncol. SLOTMAN B, SENAN S. Slotman BJ, Senan S. Quality of life. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kumar,. Oncol. Stereotactic Slotman B, Senan S. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Treatment of stage I NSCLC in elderly patients: a. Kim, & Blakeney, ). Slotman BJ, van Tinteren H, Praag JO, et al. ; (2), KIM MS et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Radiobiological. Salzman & Colburn () evidenciaram que Slotman, K. Planning of radiotherapy capacity and productivity. Experiences of case managers in providing. Radiother. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. . 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. (). , & Reijneveld, S. SLOTMAN BJ, VOS PH.